Erbitux is Poised to Threaten Avastin’s Dominance in Early Lines of Treatment for Colorectal Cancer in Europe

— A Webinar from Decision Resources

Based on our Special European Physician & Payer Forum report entitled Metastatic Colorectal Cancer in Europe: Changing Dynamics in Light of Increasing Segmentation and New Therapeutic Options, Decision Resources is offering an exclusive webinar entitled Erbitux is Poised to Threaten Avastin’s Dominance in Early Lines of Treatment for Colorectal Cancer in Europe. Because this webinar will feature major report findings, it is ONLY available to purchasers of this report.

Please contact us to learn how you can purchase this report and attend the webinar.

Metastatic Colorectal Cancer in Europe: Changing Dynamics in Light of Increasing Segmentation and New Therapeutic Options is based on surveys with 224 oncologists and interviews with 20 hospital-based payers in Germany, France, Italy, Spain and the United Kingdom. The report explores how Bristol-Myers Squibb/Eli Lilly/Merck KGaA’s Erbitux will impact the market share of Roche/Chugai’s Avastin and how Erbitux will change the competitive landscape for targeted agents in colorectal cancer in these five European countries. Launched in 2005 for colorectal cancer, Avastin has rapidly expanded its label to include four of the five most prevalent tumor types. In 2008, Avastin posted global sales close to $5 billion. Despite its significant commercial success and widespread use, Avastin is under threat from Erbitux, which is now being used to treat a subset of the first-line metastatic colorectal cancer population—patients with wild-type KRAS (Kirsten rat sarcoma 2 viral oncogene).

This webinar, presented by Decision Resources Analyst Marcus Hoyle, B.Sc., will answer the following questions:

• In the countries under study, how does the use of Avastin in first-line treatment affect how colorectal cancer is treated in the second-line?
• In what lines of therapy will Avastin and Erbitux be used to treat the wild-type KRAS patient population? In first- and second-line treatment, which drug will be used the most – Avastin or Erbitux?
• According to surveyed European oncologists, how will KRAS testing influence clinical practice in the treatment of colorectal cancer?
• How do surveyed experts expect the uptake and reimbursement of KRAS testing to impact the colorectal cancer drug market?

Mr. Hoyle will conduct a live Q & A session after the presentation.

Registration

Erbitux is Poised to Threaten Avastin’s Dominance in Early Lines of Treatment for Colorectal Cancer in Europe

December 16, 2009 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).

To learn how you can purchase this report and attend the webinar, please contact us using the information below.

Contact Us

In North America — Steve Silvestro at 781-296-2626 or ssilvestro@dresources.com

In Europe — Kaj van Langendonck at +32-2-357-06-14 or kvanlangendonck@decisionresources.be

In Japan — Makiko Yoshimoto at +81-3-5401-2615 or makiko@dresources.jp

Terms of Use | Privacy Policy | Contact Us | Careers

Decision Resources • 260 Charles Street • Waltham, MA 02453

Register to receive our latest offers. You are receiving this email because you have previously requested information from Decision Resources.

© 2009 Decision Resources, Inc. All rights reserved.